MET and non-small cell lung carcinoma: NCT01610336 (PI in China: Yi-long Wu, Guangdong General Hospital, China) is a phase Ib/II study that aims to assess the safety and efficacy of escalating doses of capmatinib plus gefitinib in patients with c-MET-positive, EGFR-mutant NSCLC.